These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 32044317)

  • 21. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
    Duarte SMB; Stefano JT; Oliveira CP
    Ann Hepatol; 2019; 18(3):416-421. PubMed ID: 31036494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
    Villard A; Boursier J; Andriantsitohaina R
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.
    Xue L; Deng Z; Luo W; He X; Chen Y
    Front Cell Infect Microbiol; 2022; 12():759306. PubMed ID: 35860380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
    Ji Y; Yin Y; Li Z; Zhang W
    Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.
    Mokhtari Z; Gibson DL; Hekmatdoost A
    Adv Nutr; 2017 Mar; 8(2):240-252. PubMed ID: 28298269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
    Hartmann P; Schnabl B
    Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
    Chen J; Vitetta L
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.